drugset / Trial / NCT02182635

Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT02182635 ↗

Phase 3 Completed 74 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.

Timeline

Start
1998-08
Primary completion
1999-03
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ba253BINEB Unknown — —